Last SFr.270.10 CHF
Change Today -3.20 / -1.17%
Volume 1.4M
ROG On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 11:43 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (ROG) Snapshot

Open
SFr.274.00
Previous Close
SFr.273.30
Day High
SFr.275.50
Day Low
SFr.269.20
52 Week High
12/3/14 - SFr.295.80
52 Week Low
01/30/14 - SFr.233.60
Market Cap
233.1B
Average Volume 10 Days
2.1M
EPS TTM
SFr.12.68
Shares Outstanding
702.6M
EX-Date
03/6/14
P/E TM
21.3x
Dividend
SFr.7.80
Dividend Yield
2.89%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (ROG)

roche holding ag-genusschein (ROG) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (ROG) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (ROG) Key Developments

Roche to Discontinue Phase III Study of Gantenerumab in Early Alzheimer’s Disease

Roche has announced its plans to discontinue SCarlet RoAD (WN25203), a Phase III study of investigational anti-amyloid medicine gantenerumab in prodromal (pre-dementia) Alzheimer's disease. Gantenerumab (RG1450) is a fully human, monoclonal antibody designed to decrease levels of beta amyloid, a protein that accumulates in the brains of people with Alzheimer's disease. The decision was based as per the recommendation by the independent Data Monitoring Committee and on the results of a pre-planned futility analysis, which found no new safety signals for gantenerumab. The investigational drug also showed a similar overall safety profile as observed in the Phase I trial (NN19866). However, gantenerumab will be evaluated by Roche in the Phase III Marguerite RoAD study (WN28745) in a later stage of Alzheimer's disease or mild dementia. Furthermore, the company's two investigational medicines, an anti-amyloid antibody crenezumab and a monoamine oxidase-B inhibitor RG1577, are currently in Phase II development for the disease.

Roche Launches Cobas Liat System for Point of Care Environment

Roche announced the launch of the cobas Liat System a fast, compact, easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings. The system includes the cobas Liat Analyzer and a growing portfolio of assays, including the cobas Influenza A/B and cobas Strep A nucleic acid tests. Utilizing Nobel prize winning polymerase chain reaction (PCR) technology, the cobas Liat System, fully automates the testing process, simplifies workflow and enables healthcare professionals to perform molecular testing in a variety of settings with speed, reliability and minimal training. Definitive results are generated in 20 minutes or less to aid a treatment decision.

Roche Expands CE-IVD Claims for Organ and Tissue Testing for Next Generation Blood Screening Assays

Roche announced that the cobas MPX and cobas WNV assays can now be used for testing of human organ and tissue from cadaveric (non-heart beating) donors, expanding the range of approved uses for the cobas 6800/8800 Systems and assays in markets accepting the CE mark. The new claims for cobas MPX and cobas WNV allow for pre-transplantation testing of organ and tissue donations, protecting transplant recipients from the donation-related transmission of HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and West Nile virus (WNV). Across the European Union, the transplantation of organs from deceased donors is a critical procedure performed for over 30,000 patients each year. The urgent nature of organ transplant procedures from deceased donors requires infectious disease screening to be carried out as quickly as possible to preserve organ function prior to transplantation. The cobas MPX and cobas WNV assays, in conjunction with the cobas 6800/8800 Systems provide the fast time to results, ensuring the delivery of accurate, reliable test results to clinicians and patients at critical decision points in a patient's care. cobas MPX is a real-time PCR multiplex test covering five critical viral targets: HIV-1 Group M, HIV-1 Group O, HIV-2, HCV and HBV, from a single sample. It offers real-time detection and identification of HIV, HCV and HBV, eliminating both the need for discriminatory testing and the potential for discrepant results. Plus, the dual-target approach with amplification of separate regions of HIV-1, and dual probes for HCV, improve coverage of new virus variants. cobas WNV is a real-time PCR test for West Nile virus (WNV) that is highly sensitive for both WNV lineages 1 and 2. It also provides broad coverage of other flaviviruses that can cause transfusion-transmitted infectious diseases. cobas HEV is a real-time PCR test for hepatitis E virus (HEV), providing broad coverage of all 4 major HEV genotypes. The cobas 6800 and 8800 Systems are fully automated solutions designed for donor screening, viral load monitoring, women's health and microbiology testing. They are available in medium and high throughput models, respectively. Based on the Nobel-prize winning PCR technology, the systems are designed to deliver increased automation and throughput with shorter time to results, providing users with greater testing flexibility to increase overall workflow efficiencies. The systems provide up to 96 results in less than 3.5 hours, and a total of 384 results for the cobas® 6800 and 960 results for the cobas® 8800 in an 8 hour shift. Both systems allow for mixed batching, making it possible for labs to perform up to three tests in the same run with no pre-sorting required. The systems also enable up to eight hours (cobas 6800) and four hours (cobas 8800) of 'work-away' time with minimal user interaction.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROG:VX SFr.270.10 CHF -3.20

ROG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.98 USD +0.77
Bayer AG €114.86 EUR -0.61
General Electric Co $25.78 USD -0.05
Gilead Sciences Inc $93.79 USD +2.50
Merck & Co Inc $57.78 USD +0.32
View Industry Companies
 

Industry Analysis

ROG

Industry Average

Valuation ROG Industry Range
Price/Earnings 19.4x
Price/Sales 4.2x
Price/Book 11.8x
Price/Cash Flow 15.8x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.